- Home
- IMNM vs LXRX Comparison
IMNM vs LXRX Comparison
Compare IMNM & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMNM
- LXRX
- Stock Information
- Founded
- IMNM 2006
- LXRX 1995
- Country
- IMNM United States
- LXRX United States
- Employees
- IMNM N/A
- LXRX N/A
- Industry
- IMNM Medicinal Chemicals and Botanical Products
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- IMNM Health Care
- LXRX Health Care
- Exchange
- IMNM Nasdaq
- LXRX Nasdaq
- Market Cap
- IMNM 747.7M
- LXRX 650.7M
- IPO Year
- IMNM 2020
- LXRX 2000
- Fundamental
- Price
- IMNM $9.91
- LXRX $0.98
- Analyst Decision
- IMNM Strong Buy
- LXRX Buy
- Analyst Count
- IMNM 5
- LXRX 2
- Target Price
- IMNM $28.60
- LXRX $6.00
- AVG Volume (30 Days)
- IMNM 695.8K
- LXRX 4.3M
- Earning Date
- IMNM 11-13-2024
- LXRX 11-12-2024
- Dividend Yield
- IMNM N/A
- LXRX N/A
- EPS Growth
- IMNM N/A
- LXRX N/A
- EPS
- IMNM N/A
- LXRX N/A
- Revenue
- IMNM $10,129,000.00
- LXRX $5,229,000.00
- Revenue This Year
- IMNM N/A
- LXRX $1,212.46
- Revenue Next Year
- IMNM N/A
- LXRX $219.10
- P/E Ratio
- IMNM N/A
- LXRX N/A
- Revenue Growth
- IMNM N/A
- LXRX 886.60
- 52 Week Low
- IMNM $6.93
- LXRX $0.97
- 52 Week High
- IMNM $30.96
- LXRX $3.73
- Technical
- Relative Strength Index (RSI)
- IMNM 30.69
- LXRX 25.78
- Support Level
- IMNM $12.46
- LXRX $1.01
- Resistance Level
- IMNM $13.52
- LXRX $1.35
- Average True Range (ATR)
- IMNM 0.85
- LXRX 0.12
- MACD
- IMNM -0.15
- LXRX -0.06
- Stochastic Oscillator
- IMNM 6.71
- LXRX 0.43
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which itcan efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious disease, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP) and and IM-4320.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.